產品
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
At Psych Congress 2026, Lilly presented Phase 1 multiple-ascending-dose data for brenipatide, a long-acting dual GIP/GLP-1 receptor agonist that is already in Phase 3 trials for alcohol use disorder and major depressive disorder. GI-related adverse events occurred in 25% of both the brenipatide and placebo groups, and topline Phase 3 data are expected in early 2028.
文章預覽
SUBSCRIBE Menu SUBSCRIBE Show Search Search Query Submit Search News Drug Development Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder September 22, 2026 | 5 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print iStock, Olga Strelnikova With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obes…